AbbVie Inc. (ABBV)
The price, the headline numbers and the latest news, in one place.
AbbVie Inc. (ABBV) Stock Price, Analysis & Data
| Bid | 261.89 |
| Market Cap | 455.4B |
| Revenue (ttm) | 64.39B |
| Net Income (ttm) | 6.27B |
| 0.28 | |
| 3.55 | |
| 72.59 | |
| 15.83 | |
| P/B (ttm) | -76.72 |
| P/S (ttm) | 7.07 |
| Earnings Date | Oct 29, 2026 |
| Ask | 262.88 |
| Volume | 3,303,234 |
| Avg. Volume (20D) | 6,575,903 |
| Open | 264.60 |
| Previous Close | 265.79 |
| Day's Range | 260.31 - 265.00 |
| 52-Week Range | 190.75 - 267.47 |
| Analyst | Buy |
| Price Target | 280 (6.50%) |
| Dividends | $6.92 (2.63%) |
| Ex-Dividend Date | Jul 15, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis f...
Financial Performance
In 2025, AbbVie's revenue was 61.16B, an increase of 8.57% compared to the previous year's 56.33B. Earnings were 4.23B, a decrease of -1.22%.
Financial StatementsAnalyst Forecast
According to 29 analyst ratings, the average rating for ABBV stock is "Buy". The 12-month stock price forecast is 280, which is upside of 6.5% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $16.99B misses estimates by $0, with 10.16% YoY growth.
- EPS of 3.65 exceeds estimates by 0.04, with 22.90% YoY growth.
Analysts project revenue of ... Upgrade
